|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.410 CNY | -1.12% |
|
-2.00% | +1.38% |
Company Valuation: Guizhou Bailing Group Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 11,050 | 10,622 | 11,404 | 11,236 | 5,255 | 5,938 |
| Change | - | -3.87% | 7.37% | -1.47% | -53.23% | 12.99% |
| Enterprise Value (EV) 1 | 12,306 | 11,871 | 12,339 | 12,505 | 6,656 | 6,812 |
| Change | - | -3.53% | 3.94% | 1.34% | -46.78% | 2.36% |
| P/E | 71.2x | 84.4x | 81.6x | -27x | 193x | -54.4x |
| PBR | 2.84x | 2.69x | 2.85x | 3.2x | 1.65x | 1.88x |
| PEG | - | -4.6x | 7.3x | 0x | -2x | 0x |
| Capitalization / Revenue | 3.58x | 3.41x | 3.22x | 2.64x | 1.37x | 1.95x |
| EV / Revenue | 3.99x | 3.82x | 3.49x | 2.93x | 1.74x | 2.23x |
| EV / EBITDA | 42.1x | 36.6x | 40.4x | -41.9x | 53.6x | 30.7x |
| EV / EBIT | 62.6x | 51.7x | 60.8x | -31.1x | 339x | 63.1x |
| EV / FCF | 45x | 76.4x | 27.3x | 101x | 62.4x | 12.1x |
| FCF Yield | 2.22% | 1.31% | 3.66% | 0.99% | 1.6% | 8.26% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.11 | 0.09 | 0.1 | -0.3 | 0.02 | -0.08 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,088 | 3,112 | 3,540 | 4,263 | 3,825 | 3,049 |
| EBITDA 1 | 292.4 | 324.2 | 305.6 | -298.6 | 124.1 | 221.9 |
| EBIT 1 | 196.5 | 229.5 | 203 | -402.3 | 19.62 | 108 |
| Net income 1 | 152.4 | 124.2 | 138.2 | -414.5 | 33.62 | -104.4 |
| Net Debt 1 | 1,256 | 1,249 | 935 | 1,268 | 1,400 | 874.7 |
| Reference price 2 | 7.830 | 7.600 | 8.160 | 8.110 | 3.850 | 4.350 |
| Nbr of stocks (in thousands) | 1,411,200 | 1,397,598 | 1,397,598 | 1,385,502 | 1,365,010 | 1,365,010 |
| Announcement Date | 29/04/21 | 22/04/22 | 28/04/23 | 29/04/24 | 28/04/25 | 27/04/26 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 889M | ||
| 16.07x | 1.92x | 12.53x | 5.33% | 13.44B | ||
| 23.42x | 1.51x | 9.1x | 2.71% | 5.08B | ||
| 16.33x | 3.37x | 10.39x | 5.57% | 4.8B | ||
| 18.22x | - | - | 1.28% | 4.05B | ||
| 17.52x | 2.48x | 10.76x | 2.86% | 3.48B | ||
| 14.7x | 2.9x | 12.36x | 5.48% | 1.82B | ||
| Average | 17.71x | 2.44x | 11.03x | 3.87% | 4.79B | |
| Weighted average by Cap. | 17.60x | 2.22x | 11.34x | 4.2% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002424 Stock
- Valuation Guizhou Bailing Group Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















